Health Care • Medical/Dental Instruments
$19.25 ▲ +0.04
(+0.21%)
MKT CAP: $5.42B • VOL: 7.33M
52W L $11 52W H $24
MMED // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-04-24 | FY 2024
FILED 2025-04-25 | FY 2023
FILED 2024-04-26 |
|---|---|---|---|
| Revenue (Total Sales) | $3.10B | $2.71B | $2.47B |
| YoY Revenue Growth % | +14.3% | +10.0% | — |
| Gross Profit | $1.68B | $1.53B | $1.09B |
| Gross Margin % | 54.2% | 56.3% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$190.0M | -$146.0M | -$69.0M |
| Operating Margin % | -6.1% | -5.4% | -2.8% |
| Net Income (GAAP) | -$333.0M | -$213.0M | -$112.0M |
| EBITDA (Normalized) | -$11.6M | $8.4M | $19.9M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$197.0M | $140.0M | $41.0M |
| Capital Expenditures (CapEx) | $223.0M | $193.0M | $111.1M |
| Free Cash Flow (FCF) | -$420.0M | -$53.0M | -$70.1M |
| FCF Margin % | -13.5% | -2.0% | -2.8% |
| Return on Invested Capital (ROIC %) | -3.9% | -3.0% | -3.0% |
| Cash & Short-Term Equivalents | $10.0M | $358.4M | $327.7M |
| Total Debt (Short + Long Term) | $396.4M | $762.4M | $697.0M |
| Total Stockholders' Equity | $3.46B | $3.48B | $1.43B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MMED.